Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NT-0796 is a novel chemotype, designed as an orally bioavailable, brain penetrant NLRP3 inhibitor. NT-0796 has completed its Phase 1 study confirming brain penetration with excellent pharmacokinetic (PK) & pharmacodynamic (PD) profiles.
Lead Product(s): NT-0796
Therapeutic Area: Neurology Product Name: NT-0796
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020